Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
6
×
deals
6
×
life sciences
national blog main
san francisco blog main
6
×
vc
6
×
biotech
national top stories
new york blog main
san francisco top stories
startups
new york top stories
san diego blog main
boston
gene therapy
san diego top stories
crispr
gene editing
hemophilia
illumina
indiana blog main
ipo
raleigh-durham blog main
rtw investments
san francisco
seattle blog main
venture capital
acetylon pharmaceuticals
adeno-associated virus
administration
alexandria venture investments
altitude life science ventures
alzheimer's
ambys medicines
american society of gene and cell therapy
amgen
arch venture partners
arrowmark partners
azacitidine
What
gene
medicines
startup
bio
biotech
developing
diseases
new
patients
therapy
aiming
aims
ambys
approach
based
becker
beta
big
billions
bionics
blood
called
closed
control
create
crispr
crude
cutting
deadly
deal
debuted
debuts
despite
device
diabetes
diagnostic
dollars
driven
drugs
eaton
Language
unset
Current search:
vc
×
deals
×
" boston top stories "
×
" san francisco blog main "
×
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?